AtriCure (NASDAQ:ATRC) Stock Falls 6.2% – Should You Sell?

AtriCure, Inc. (NASDAQ:ATRC) dropped 6.2% during trading on Thursday. The company traded as low as $52.60 and last traded at $52.7120. 1,021,907 shares changed hands during mid-day trading, an increase of 17% from the average session volume of 875,922 shares. The stock had previously closed at $56.20.

Analyst Upgrades and Downgrades

ATRC has been the subject of several research reports. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. UBS Group dropped their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Zacks Research lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Stifel Nicolaus set a $65.00 price target on shares of AtriCure in a research report on Thursday, September 17th. Finally, Freedom Capital downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Friday. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $53.30.

AtriCure Stock Up 2.9%

The company has a market cap of $2.80 billion, a P/E ratio of 262.58 and a beta of 1.24. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The firm has a fifty day moving average price of $49.44 and a 200 day moving average price of $36.38.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the prior year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other AtriCure news, insider Vinayak Doraiswamy sold 6,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total transaction of $233,280.00. Following the transaction, the insider directly owned 86,511 shares in the company, valued at approximately $3,363,547.68. This represents a 6.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Salvatore Privitera sold 7,763 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50. Following the completion of the transaction, the insider directly owned 150,921 shares in the company, valued at $7,923,352.50. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,868 shares of company stock valued at $3,317,897 over the last 90 days. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Institutional investors have recently modified their holdings of the business. Tidal Investments LLC grew its holdings in AtriCure by 46.2% during the 2nd quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock worth $534,000 after acquiring an additional 6,034 shares during the period. WINTON GROUP Ltd acquired a new position in shares of AtriCure in the 2nd quarter valued at $1,002,000. Engineers Gate Manager LP lifted its stake in shares of AtriCure by 12.3% in the 2nd quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company’s stock valued at $1,348,000 after purchasing an additional 5,283 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of AtriCure in the 2nd quarter worth $46,000. Finally, Allworth Financial LP boosted its position in shares of AtriCure by 372.8% in the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock worth $43,000 after purchasing an additional 1,204 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.